ESMO 2017.

Oasi ALK

Contributi

Video, Slide, Cartelle Zip

ESMO 2017 – ALK – 11/09/2017

1298O_PR - Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
e
1299O_PR - Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

A cura di Filippo de Marinis

VISUALIZZA
Diventa socio AIOT, entra e compila il form di registrazione.
alt text